Program in Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada.
Division of Haematology/Oncology, CancerCare Manitoba, Winnipeg, Canada.
Clin Genet. 2018 Feb;93(2):320-328. doi: 10.1111/cge.13158. Epub 2017 Dec 27.
Diamond-Blackfan anemia (DBA) features hypoplastic anemia and congenital malformations, largely caused by mutations in various ribosomal proteins. The aim of this study was to characterize the spectrum of genetic lesions causing DBA and identify genotypes that correlate with phenotypes of clinical significance. Seventy-four patients with DBA from across Canada were included. Nucleotide-level mutations or large deletions were identified in 10 ribosomal genes in 45 cases. The RPS19 mutation group was associated with higher requirement for chronic treatment for anemia than other DBA groups. Patients with RPS19 mutations, however, were more likely to maintain long-term corticosteroid response without requirement for further chronic transfusions. Conversely, patients with RPL11 mutations were less likely to need chronic treatment. Birth defects, including cardiac, skeletal, hand, cleft lip or palate and genitourinary malformations, also varied among the various genetic groups. Patients with RPS19 mutations had the fewest number of defects, while patients with RPL5 had the greatest number of birth defects. This is the first study to show differences between DBA genetic groups with regards to treatment. Previously unreported differences in the rate and types of birth defects were also identified. These data allow better patient counseling, a more personalized monitoring plan, and may also suggest differential functions of DBA genes on ribosome and extra-ribosomal functions.
Diamond-Blackfan 贫血(DBA)的特征为再生障碍性贫血和先天性畸形,主要由各种核糖体蛋白的突变引起。本研究旨在描述导致 DBA 的遗传病变谱,并确定与具有临床意义的表型相关的基因型。研究纳入了来自加拿大各地的 74 名 DBA 患者。在 45 例患者中,在 10 个核糖体基因中发现了核苷酸水平的突变或大片段缺失。与其他 DBA 组相比,RPS19 突变组对贫血的慢性治疗需求更高。然而,RPS19 突变的患者更有可能长期维持皮质类固醇反应,而无需进一步的慢性输血。相反,RPL11 突变的患者不太需要慢性治疗。各种遗传组之间的出生缺陷也不同,包括心脏、骨骼、手部、唇裂或腭裂以及泌尿生殖系统畸形。RPS19 突变的患者缺陷最少,而 RPL5 突变的患者缺陷最多。这是第一项研究表明 DBA 遗传组在治疗方面存在差异。还发现了以前未报道的出生缺陷发生率和类型的差异。这些数据可以更好地为患者提供咨询,制定更个性化的监测计划,并且还可能提示 DBA 基因在核糖体和核糖体外功能上的差异作用。